260 related articles for article (PubMed ID: 18352850)
21. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
Au GG; Lincz LF; Enno A; Shafren DR
Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
[TBL] [Abstract][Full Text] [Related]
23. Remission of disseminated cancer after systemic oncolytic virotherapy.
Russell SJ; Federspiel MJ; Peng KW; Tong C; Dingli D; Morice WG; Lowe V; O'Connor MK; Kyle RA; Leung N; Buadi FK; Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A
Mayo Clin Proc; 2014 Jul; 89(7):926-33. PubMed ID: 24835528
[TBL] [Abstract][Full Text] [Related]
24. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic viruses: what to expect from their use in cancer treatment.
Terrível M; Gromicho C; Matos AM
Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG
Hum Vaccin Immunother; 2015; 11(7):1573-84. PubMed ID: 25996182
[TBL] [Abstract][Full Text] [Related]
28. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
Ruiz AJ; Hadac EM; Nace RA; Russell SJ
J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
[TBL] [Abstract][Full Text] [Related]
30. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
31. Naturally oncolytic viruses.
Roberts MS; Lorence RM; Groene WS; Bamat MK
Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S
Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439
[TBL] [Abstract][Full Text] [Related]
33. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
34. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.
Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W
Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
Thirukkumaran CM; Shi ZQ; Nuovo GJ; Luider J; Kopciuk KA; Dong Y; Mostafa AA; Thakur S; Gratton K; Yang A; Chin AC; Coffey MC; Jimenez-Zepeda VH; Stewart D; Chesi M; Bergsagel PL; Morris D
Blood Adv; 2019 Mar; 3(5):797-812. PubMed ID: 30850386
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
37. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic virotherapy for urological cancers.
Delwar Z; Zhang K; Rennie PS; Jia W
Nat Rev Urol; 2016 Jun; 13(6):334-52. PubMed ID: 27215429
[TBL] [Abstract][Full Text] [Related]
39. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M; Jaime-Ramirez AC; Yan P; Benson DM; Byrd JC; Baiocchi R; Kaur B; Hofmeister CC; Pichiorri F
Mol Cancer Ther; 2016 May; 15(5):830-41. PubMed ID: 26809490
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapeutic potential of oncolytic vaccinia virus.
Thorne SH
Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
